CONSENT AND FIRST LOAN MODIFICATION AGREEMENTConsent and First Loan Modification Agreement • March 9th, 2012 • Zalicus Inc. • Pharmaceutical preparations
This Consent and First Loan Modification Agreement (this “Consent”) is entered into as of February 15, 2012 by and among OXFORD FINANCE LLC, a Delaware limited liability company (as successor in interest to OXFORD FINANCE CORPORATION, Delaware corporation), with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), ZALICUS, INC., a Delaware corporation, with offices located at 245 First Street, Third Floor, Cambridge, Massachusetts 02142 (“Zalicus”) and ZALICUS PHARMACEUTICALS LTD., a corporation organized under the laws of British Columbia, Canada (“Zalicus Canada” and together with Zalicus, individually and collectively, jointly and severally, “Borrower”).
CONSENT AND FIRST LOAN MODIFICATION AGREEMENTConsent and First Loan Modification Agreement • May 7th, 2015 • Oclaro, Inc. • Semiconductors & related devices
This Consent and First Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of February 19, 2015 (the “First Loan Modification Effective Date”), by and among (i) SILICON VALLEY BANK, a California corporation with a loan production office located at 2400 Hanover Street, Palo Alto, CA 94304 (“Bank”), (ii) OCLARO, INC., a Delaware corporation (“Parent”) and (iii) OCLARO TECHNOLOGY LIMITED, a company incorporated under the laws of England and Wales, with company number 02298887 and its registered address at Caswell Towcester, Northamptonshire NN12 8EQ, UK (“Borrower”).
CONSENT AND FIRST LOAN MODIFICATION AGREEMENTConsent and First Loan Modification Agreement • March 26th, 2008 • Pharmathene, Inc • Pharmaceutical preparations
This Consent and First Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of March 20, 2008, by and among SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 8020 Tower Crescent Drive, Suite 475, Vienna, Virginia 22182 (“SVB”), as agent (“Agent”), and the Lenders, SVB and OXFORD FINANCE CORPORATION (“Oxford”), and PHARMATHENE U.S. CORPORATION (formerly known as PHARMNTHENE, INC.), a Delaware corporation with its chief executive office located at (“Borrower”).
CONSENT AND FIRST LOAN MODIFICATION AGREEMENTConsent and First Loan Modification Agreement • November 14th, 2011 • Horizon Pharma, Inc. • Pharmaceutical preparations
This Consent and First Loan Modification Agreement (this “Consent”) is entered into as of August 17, 2011 by and among (a) HORIZON PHARMA USA, INC., a Delaware corporation (formerly called HORIZON THERAPEUTICS, INC.) (“Horizon”), HORIZON PHARMA, INC., a Delaware corporation (“Horizon Pharma”), HORIZON PHARMA (UK) LIMITED, a company registered under the laws of England and Wales with registration number 5819120, with its registered offices in the United Kingdom at c/o Arnold & Porter (UK) LLP, Tower 42, 24 Old Broad Street, London EC2N 1HQ (“Horizon UK”, and together with Horizon and Horizon Pharma, each a “Borrower” and, collectively, jointly and severally, the “Borrowers”), (b) the Lenders listed on the signature pages to the Loan Agreement referenced below or otherwise party thereto from time to time (the “Lenders”) and (c) OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as administrat
